Masimo
Masimo is a global medical technology company that develops noninvasive patient monitoring devices, led by its SET pulse oximetry platform, serving hospitals, neonatal ICUs, government healthcare, and home health programs across more than 30 countries.
- Company typePrivate
- Founded1989
- HeadquartersIrvine, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Masimo does
Masimo is a global medical technology company that develops and manufactures noninvasive patient monitoring devices for hospitals and healthcare systems. The company's core platform is Masimo SET (Signal Extraction Technology) pulse oximetry, which uses advanced signal processing algorithms and dedicated sensor designs to deliver accurate oxygen saturation and pulse rate readings through patient motion and low perfusion, including across all skin tones. Built on this foundation, the rainbow Pulse CO-Oximetry platform extends monitoring to multiple blood constituents (SpHb, SpCO, SpMet, ORi), with additional modalities covering brain function (SedLine), regional oximetry (O3), hemodynamics (LiDCO), capnography (NomoLine), acoustic respiration rate (RRa), and the recently FDA-cleared AI-enabled opioid-induced respiratory depression detection on the wearable Radius VSM monitor.
Masimo serves acute care hospitals, academic medical centers, neonatal intensive care units, emergency medical services, government and military healthcare providers, contract research organizations, and home health programs in more than 30 countries. Its go-to-market combines a direct enterprise sales force and clinical specialist team targeting large hospital systems with an OEM licensing channel that embeds Masimo SET technology into 250+ third-party monitors manufactured by partners such as Philips, GE Healthcare, and Draeger. Revenue is generated through capital equipment sales (Root, Radical-7, Rad-97, Radius VSM, handhelds), a high-margin recurring stream of single-patient-use sensors and replacement tapes, and technology licensing royalties. Following the 2025 divestiture of the Sound United consumer audio business and the June 2026 closing of Danaher Corporation's $9.9 billion acquisition, Masimo now operates as a wholly-owned subsidiary within Danaher's Diagnostics segment, with a sharpened focus on hospital patient monitoring.
Masimo firmographics
Firmographics- Name
- Masimo
- Legal name
- Masimo Corporation
- Website
- https://masimo.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Acquired
- Headcount range
- 1,001–5,000 employees
- Short description
- Masimo is a global medical technology company that develops noninvasive patient monitoring devices, led by its SET pulse oximetry platform, serving hospitals, neonatal ICUs, government healthcare, and home health programs across more than 30 countries.
- Ownership category
- akta.pro rank
Masimo industry classification
Industry- Product category
- Patient Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management) (HLALAFAL)
- akta.pro secondary industries
- AI/Analytics for RPM (Risk Stratification, Alerts, Predictive) (HLACAFAM), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where Masimo is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Masimo business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- Patient Monitoring Hardware: Sale of patient monitoring devices and platforms including Root, Radical-7, Rad-97, handheld monitors, and wearable devices. These are capital equipment purchases with multi-year device lifecycles.
- Sensors and Consumables: Recurring revenue from single-patient-use sensors (RD SET, rainbow sensors), replacement tapes, and cannulas. The company emphasizes sustainability through sensor recycling programs and replacement tape options that extend sensor life by 3.6x.
- OEM Technology Licensing: Integration of Masimo SET technology into 250+ third-party monitors from other manufacturers. Masimo provides technology licensing to original equipment manufacturers who incorporate the technology into their devices.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise hospital contracts with volume-based pricing |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Masimo product offering
Product offeringCore offering
Masimo develops, manufactures, and sells noninvasive patient monitoring devices and technologies used in hospitals and clinical settings. Its core offering is the SET (Signal Extraction Technology) pulse oximetry platform, expanded through rainbow Pulse CO-Oximetry into multi-parameter monitoring, and complemented by brain function, hemodynamic, capnography, wearable, and remote patient monitoring products sold with recurring single-patient-use sensors.
Product overview
Masimo offers a comprehensive patient monitoring ecosystem centered on its proprietary SET (Signal Extraction Technology) pulse oximetry platform. The core Root monitoring platform serves as an expandable hub that integrates multimodal monitoring capabilities including bedside monitors (Radical-7, Rad-97), wearable devices (Radius VSM with AI-enabled OIRD detection, MightySat Rx, Masimo W1), handheld devices (Rad-G, Rad-57), and advanced sensors. The rainbow Pulse CO-Oximetry technology extends monitoring with multi-wavelength sensors for hemoglobin, methemoglobin, and carboxyhemoglobin. Specialized monitoring includes SedLine brain function monitoring, O3 regional oximetry, LiDCO hemodynamic monitoring, NomoLine capnography, and rainbow Acoustic Monitoring for respiration rate. Connectivity solutions (iSirona, Iris Gateway) enable integration with third-party devices and EMR systems, while Patient SafetyNet and Masimo SafetyNet provide remote monitoring and telehealth capabilities.
Differentiator
Problem solved
Functional benefit
Brands
- Masimo SET: Signal Extraction Technology pulse oximetry that measures accurately through motion and low perfusion
- rainbow
- SedLine
- O3
- LiDCO
- Radius
- MightySat
- NomoLine
- Patient SafetyNet
Products and services
- Root Patient Monitoring Platform
- Radical-7 Bedside Pulse CO-Oximeter
- Rad-97 Bedside Monitor
- Radius VSM Wearable Continuous Monitor
- MightySat Rx Fingertip Pulse Oximeter
- Masimo W1 Wearable Health Monitor
- Rad-G Handheld Pulse Oximeter
- Rad-57 Handheld Pulse CO-Oximeter
- EMMA Portable Capnograph
- LiDCO Hemodynamic Monitoring System
- SedLine Brain Function Monitoring
- O3 Regional Oximetry
- NomoLine Capnography
- Patient SafetyNet Remote Monitoring System
- Masimo SafetyNet Telehealth Platform
- iSirona Medical Device Integration
- Iris Gateway Connectivity Platform
- RD SET Single-Patient-Use Sensors
- RD rainbow Multi-Wavelength Sensors
Quantifiable outcome
- 86% reduction in false alarms over 156 monitored hours in non-sedated neonates
- +5 more outcomes
Companies that use Masimo
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
Masimo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability2 records
Feature10 records
Masimo partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- PhilipscoreMasimo and Philips expanded their strategic partnership to enhance patient monitoring integration. The collaboration enables deeper integration of Masimo's monitoring parameters into Philips' patient monitoring ecosystem, including compatibility with Philips' IntelliVue monitors and healthcare IT platforms.
- Samsung/HarmanminorSamsung's Harman subsidiary acquired Masimo's U.S. audio business (formerly Sound United) for approximately 500 billion won. Added premium audio brands including Bowers & Wilkins, Denon, and Marantz to Harman's portfolio.
- OEM Monitor Partners (250+)coreMasimo SET technology is integrated into over 250 third-party monitors from leading patient monitoring equipment manufacturers including Philips, GE Healthcare, Draeger, and others. These OEM partnerships enable broad distribution of Masimo technology through established medical device channels.
- WHO, UNICEF, PAHO, World Bank, Global FundminorMasimo's Global Health division provides direct access to patient monitoring technologies for major international humanitarian organizations serving underserved communities and global health initiatives.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
Masimo competitors and assessment
Company assessmentDirect peers
- GE HealthCare: GE HealthCare competes head-to-head with Masimo in hospital patient monitoring and is also an OEM licensee of Masimo SET/rainbow technology. Overlap spans bedside monitors, anesthesia monitoring, and integrated care-area solutions purchased by the same health system buyers.
- Nihon Kohden: Nihon Kohden is a Japan-based patient monitoring specialist with strong presence in Asia and growing U.S. share, directly competing with Masimo in bedside monitors, EEG and pulse oximetry. Comparable hospital-focused business model with installed-base sensors and OEM integrations.
- Drägerwerk: Draeger is a leading ICU, OR and neonatal monitoring vendor that both competes with Masimo and licenses SET for its own monitor platforms. The companies sell into overlapping anesthesia, NICU and critical care buying committees across Europe and the U.S.
- Medtronic: Medtronic owns Nellcor pulse oximetry and a broad patient monitoring portfolio that directly competes with Masimo SET in hospitals. Both companies sell pulse oximeters, sensors and integrated bedside monitoring to the same acute-care customers.
- Royal Philips: Philips is one of Masimo's largest OEM partners (IntelliVue platform) and a direct competitor in multiparameter patient monitoring across ICU, OR and general care. Philips and Masimo increasingly compete for hospital monitoring contracts while also deepening integration partnerships.
- Edwards Lifesciences: Edwards' hemodynamic monitoring franchise (FloTrac, ClearSight, HemoSphere) competes with Masimo's LiDCO-based cardiac output and stroke volume offerings in the OR and ICU. Both companies target perioperative goal-directed therapy protocols with continuous beat-to-beat hemodynamic data.
Broad incumbents
- Mindray: Mindray is a large Chinese medical device manufacturer offering patient monitoring, pulse oximetry and in-vitro diagnostics to hospitals globally. While broader than Masimo, it is a meaningful competitor in mid-tier hospital monitors and OEM-grade pulse oximetry, particularly in emerging markets.
- ICU Medical: ICU Medical owns the Smiths Medical portfolio including patient monitoring and infusion devices that overlap with Masimo's acute-care footprint. Both companies sell into hospital med-surg, ICU and anesthesia workflows, though ICU Medical is more diversified across IV therapy and critical care.
Emerging players
- Nonin Medical: Nonin is a U.S.-based specialist in pulse oximetry and capnography devices, competing most directly with Masimo's handheld and fingertip offerings (Rad-G, Rad-57, MightySat). A focused niche player with overlapping sensor technology but a smaller commercial footprint than Masimo.
- Spacelabs Healthcare: Spacelabs provides patient monitoring, anesthesia delivery and diagnostic cardiology solutions to hospitals and clinics, competing with Masimo in multiparameter bedside monitoring. Comparable focus on smaller and mid-sized hospital systems and on cardiology/cardiac telemetry.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Masimo social profiles
Digital presenceMasimo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Masimo leadership team
Management profileNumber of profiles
Profiles5 records
Masimo subsidiaries and ownership
Company hierarchySubsidiaries3 records
Masimo funding detail
Funding detailFunding overview
Funding rounds4 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Masimo M&A and investment
M&A and investmentM&A6 records
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Masimo
What does Masimo do?
Masimo develops, manufactures, and sells noninvasive patient monitoring devices and technologies used in hospitals and clinical settings. Its core offering is the SET (Signal Extraction Technology) pulse oximetry platform, expanded through rainbow Pulse CO-Oximetry into multi-parameter monitoring, and complemented by brain function, hemodynamic, capnography, wearable, and remote patient monitoring products sold with recurring single-patient-use sensors.
Is Masimo a public or private company?
Masimo is a private company. It is classified as corporate owned and is currently acquired.
When was Masimo founded?
Masimo was founded in 1989. It employs 1,001 to 5,000 people.
Where is Masimo based?
Masimo is headquartered in Irvine, United States, in the North America region.
How does Masimo make money?
Three revenue lines are on record. Patient Monitoring Hardware is the primary driver. The others are sensors and Consumables and OEM Technology Licensing.
Who are Masimo's main competitors?
Direct peers on record are GE HealthCare, Nihon Kohden, Drägerwerk, Medtronic, Royal Philips and Edwards Lifesciences. Broad incumbents are Mindray and ICU Medical. Emerging players are Nonin Medical and Spacelabs Healthcare.
Does Masimo have an API?
No public API is recorded for Masimo.
What industry is Masimo in?
Masimo's product category is Patient Monitoring Devices. Its primary akta.pro industry code is HLALAFAL, Multi-Condition RPM Platforms & Care Orchestration (device-agnostic, population management), with a secondary code of HLACAFAM, AI/Analytics for RPM (Risk Stratification, Alerts, Predictive). Its NAICS code is 334510 and its SIC code is 3845.